CES is a treatment modality that has been neglected by mainstream medicine for the treatment of anxiety, depression, and insomnia. Selective serotonin reuptake inhibitors (SSRIs) are known as the gold standard for the treatment of depression. However, CES is now more relevant because of recent government warnings relating to the use of SSRIs.
Thus far, CES has not demonstrated any of the adverse effects now associated with SSRIs. At the same time, while there is no shortage of antidepressant research, today's peer-reviewed literature has a relative dearth of CES reports. The companies that produce these devices are small and as yet unable to support the high-budget standards of double-blinded, randomized, institutional review board-controlled studies. A surprising number of CES studies in the peer-reviewed literature have been done without funding.
CES in the United States has received Food and Drug Administration marketing clearance for the treatment of anxiety, depression, and insomnia. CES devices are sold over the counter in Europe and other parts of the world. Mood disordered alcoholics have shown increased activity of the enzyme MAO-B in the spinal fluid after 20 CES treatments (3). Patients with treatment-resistant depression have shown significant (P < 0.0089) elevations in plasma serotonin (4). Increases in cerebrospinal fluid levels of [beta]-endorphins up to 219%, plasma endorphins up to 98%, and cerebrospinal fluid serotonin up to 200% have been demonstrated in normal volunteers receiving 20 minutes of CES (5). A recent annotated bibliography of CES by Kirsch (6) details 126 human and 29 experimental animal studies of CES conducted over the past 40 years. More than half the studies cited are from the peer-reviewed literature. The majority of the studies were double-blinded and conducted at major American universities. In aggregate, there were 6,007 patients treated under varying research conditions, with 4,541 actually receiving CES treatment. One hundred twelve (89%) of the studies reported positive outcomes. Seventeen studies followed up the patients to assess any continued results after one week and up to two years, and all the patients showed at least some residual effects after one or a series of treatments.
CES is both noninvasive and considerably less expensive than pharmaceutical treatments. Neurosurgical implantation techniques of deep brain-stimulating electrodes and vagal nerve stimulators that are currently used and studied for the treatment of affective disorders are also more expensive. Furthermore, while CES does require continuing medical assessment and supervision, the same caveat applies to all the antidepressants and other medications for the treatment of anxiety, depression, and insomnia in today's Physician's Desk Reference. The patient safety movement and burgeoning internet resources are working to increase the number of patients more actively involved in their own care. CES deserves to be a modality in the armamentarium not only for chronic pain but for reducing or occasionally replacing the amount of medication necessary in the treatment of anxiety and depression. CES is not a miraculous modality, but it's definitely worth a try.
About the Author
For more information, please visit: http://www.fisherwallace.com/.
1. Institute of Medicine. In Kohn LT, Corrigan JM, Donaldson MS (eds). To Err Is Human: Building a Safer Health System. Washington, DC, National Academy Press, 2000.
2. Institute for Safe Medication Practices [http://www.ismp.org/]. 1800 Byberry Road, Suite 810, Huntingdon Valley, PA 19006 Voice: 215.947.7797 Fax: 215.914.1492. Email email@example.com.
3. Krupisky EM, Burakov AM, Karandashova GF, et al. The administration of transcranial electric treatment for affective disturbances therapy and alcoholic patients. Drug Alcohol Depend 1991;27:1-6.
4. Shealy CN, Cady RK, Wilkie RG, et al. Depression: a diagnostic, neurochemical profile and therapy with cranial electrotherapy simulation (CES). J Neurol Orthop Med Surg 1989;10:319-321.
5. Shealy CN, Cady RK, Wilkie RG, et al. Cerebral Spinal Fluid and Plasma Neurochemicals: Response to Cranial Electrotherapy Stimulation. J Neurol Orthop Med Surg 1998;18:94-97.
6. Kirsch DL. The Science Behind Cranial Electrotherapy Stimulation. Edmonton, Alberta, Canada. Medical Scope Publishing Corporation, 2002.